Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lines Skin Clear all
Completed Phase 2 Interventional Results available

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

NCT00493636
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Sorafenib, Placebo, Capecitabine
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
44
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 22, 2026, 11:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

NCT00924001
View directory record Official record
Conditions
Melanoma, Malignant Melanoma, Melanoma, Experimental
Interventions
DMF5 Melanoma Reactive TIL, Cyclophosphamide, Fludarabine, Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 22, 2026, 11:51 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

NCT04540900
View directory record Official record
Conditions
Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
Interventions
KB301, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
4
States / cities
Campbell, California • Newport Beach, California • Rancho Santa Margarita, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 22, 2026, 11:51 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

NCT00895271
View directory record Official record
Conditions
Primary Immunodeficiency, DOCK8, Virus Susceptibility
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 2 Interventional

Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer

NCT00005963
View directory record Official record
Conditions
Breast Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
21
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 22, 2026, 11:51 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

NCT00880009
View directory record Official record
Conditions
Breast Cancer
Interventions
Bosutinib, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Whittier, California • Joliet, Illinois • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 2 Interventional Results available

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

NCT04382664
View directory record Official record
Conditions
Malignant Melanoma
Interventions
UV1, Sargramostim, Ipilimumab, Nivolumab
Biological
Lead sponsor
Ultimovacs ASA
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 2 Interventional

Phase II, 2nd Line Melanoma - RAND Monotherapy

NCT00612664
View directory record Official record
Conditions
Melanoma
Interventions
Anti-CD137 (4-1BB) (BMS-663513)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Park Ridge, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

NCT01491737
View directory record Official record
Conditions
Breast Cancer
Interventions
Pertuzumab, Trastuzumab, Aromatase Inhibitor, Induction Chemotherapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

NCT00667251
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, docetaxel, lapatinib ditosylate, paclitaxel
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
53
States / cities
Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 22, 2026, 11:51 AM EDT
Recruiting Not applicable Interventional

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

NCT04030507
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Interventions
MRI
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

NCT00217672
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, Docetaxel
Biological · Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 3 Interventional Results available

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

NCT00373256
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sunitinib, paclitaxel, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
241
States / cities
Bessemer, Alabama • Birmingham, Alabama • Daphne, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 22, 2026, 11:51 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

NCT03742102
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 2 Interventional Results available

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

NCT00696072
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dasatinib, Letrozole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Jul 22, 2026, 11:51 AM EDT
Recruiting Phase 3 Interventional

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions
SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

NCT01107665
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma
Interventions
Pazopanib and Paclitaxel
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jul 22, 2026, 11:51 AM EDT
Terminated Phase 2 Interventional Results available

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

NCT00281528
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
ABI-007 (Abraxane), bevacizumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 2 Interventional

Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer

NCT00002937
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, valspodar
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Jul 22, 2026, 11:51 AM EDT
Terminated Phase 2 Interventional Results available

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

NCT01207102
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abraxane, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2014 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Glue Versus Suture for Securing Radial Arterial Lines

NCT06589284
View directory record Official record
Conditions
Arterial Catheters, Catheter Related Complication
Interventions
Silk 0-0 suture covered by chlorhexidine gluconate dressing, 2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing
Procedure
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of Subcuticular Skin Closure Versus Steri-strip S Closure

NCT00727025
View directory record Official record
Conditions
Breast Hypertrophy, Abdominal Elastosis, Breast Reconstruction
Interventions
wound closure device (Steri-Strip™)
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Jul 22, 2026, 11:51 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

NCT00856414
View directory record Official record
Conditions
Skin Aging
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Jul 22, 2026, 11:51 AM EDT
Terminated No phase listed Observational

Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

NCT01068470
View directory record Official record
Conditions
Melanoma, Kidney Cancer
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Beaumont, California
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Jul 22, 2026, 11:51 AM EDT